Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023GlobeNewsWire • 04/13/23
Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 02/24/23
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/09/23
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023GlobeNewsWire • 02/02/23
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company's Vision to Transform Patient Outcomes in Rare DiseasesGlobeNewsWire • 01/09/23
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerGlobeNewsWire • 01/03/23
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023GlobeNewsWire • 12/21/22
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and ExpositionGlobeNewsWire • 12/12/22
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual MeetGlobeNewsWire • 12/10/22
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult PatientsGlobeNewsWire • 11/10/22